FDA Approves 2 New Anti-MRSA Agents

The U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee voted unanimously to approve two antibacterial treatments for methicillin-resistant Staphylococcus aureus skin infections.

The treatments are Sivextro (tedizolid phosphate), from Cubist Pharmaceuticals, and Dalvance (vancomycin-linezolid combination), from Durata Therapeutics. Sivextro is a daily oral or intravenous drug, while Dalvance is a weekly IV treatment.

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

Both drugs successfully completed phase III clinical trials to be considered for approval, according to a Medscape report. However, the drugs will be subject to postmarket safety monitoring, as concerns raised during public hearings included a lack of diversity in the study populations and use of drug-to-drug efficacy comparisons instead of drug-to-disease efficacy comparisons.

More Articles on Infection Control & Clinical Quality:

Lucrative Treatments Overlooked for Lists of Unnecessary Procedures

Direct Patient Education Improves Adherence to Drug-Use Guidelines

3 Tips to Prevent Cardiac SSIs From Cleveland Clinic

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars